source
- BMS reports positive mid-stage results for arlo-cel in heavily pre-treated myeloma patientsBMS said its CAR T therapy arlo-cel, formally arlocabtagene autoleucel, achieved positive results in a registrational mid-stage study for relapsed and refractory multiple myeloma. The open-label,…
- TwoStep Therapeutics raises $62.5 million Series A backed by Pfizer and Merck KGaA venture groupsTwoStep Therapeutics, a cancer biotech, announced a $62.5 million Series A financing to advance its novel approach to antibody-drug conjugates and radioligand therapies. The round was supported by…